loader2
Login Open ICICI 3-in-1 Account
  • Text Size
  • Text to Speech
  • Color Contrast
  • Pause Animations

Procter & Gamble Health Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Procter & Gamble Health Ltd. 02 Nov 2026 16:37 PM

Q2FY27 Quarterly Result Announced for Procter & Gamble Health Ltd.

Pharmaceuticals company Procter & Gamble Health announced Q2FY27 results

Financial Highlights:

  • Total Income: Standalone Total Income reached Rs 38,638 lakh in Q2FY27, showing an increase of 5.11% QoQ from Rs 36,759 lakh in Q1FY27 and registering a growth of 17.38% YoY compared to Rs 32,987 lakh in Q2FY26. For H1FY27, Standalone Total Income stood at Rs 75,397 lakh, up by 12.09% YoY from Rs 67,264 lakh in H1FY26.
  • Revenue from Operations: Standalone Revenue from Operations stood at Rs 38,249 lakh in Q2FY27, indicating a growth of 5.16% QoQ from Rs 36,371 lakh in Q1FY27 and up by 17.72% YoY against Rs 32,492 lakh in Q2FY26. For H1FY27, Revenue from Operations reached Rs 74,620 lakh, representing an increase of 12.44% YoY compared to Rs 66,366 lakh in H1FY26.
  • Profit Before Tax (PBT): Standalone PBT was Rs 15,005 lakh in Q2FY27, representing a growth of 16.21% QoQ over Rs 12,912 lakh in Q1FY27 and an increase of 26.07% YoY from Rs 11,902 lakh in Q2FY26. For H1FY27, Standalone PBT reached Rs 27,917 lakh, a growth of 34.33% YoY against Rs 20,783 lakh in H1FY26.
  • Net Profit for the Period (PAT): Standalone PAT was Rs 11,151 lakh in Q2FY27, up 15.98% QoQ compared to Rs 9,615 lakh in Q1FY27 and recording a growth of 25.94% YoY against Rs 8,854 lakh in Q2FY26. For H1FY27, Standalone PAT reached Rs 20,766 lakh, a YoY expansion of 34.22% from Rs 15,472 lakh in H1FY26.
  • Earnings Per Share (EPS) - Standalone Basic and Diluted EPS reached Rs 67.18 in Q2FY27, increasing by 73.28% QoQ against Rs 38.77 in Q1FY27 and up 25.95% YoY over Rs 53.34 in Q2FY26. For H1FY27, Standalone EPS before exceptional items was Rs 105.94, a growth of 13.66% YoY against Rs 93.21 in H1FY26.

Milind Thatte, Managing Director, P&G Health India, said: “We have delivered another strong quarter with double-digit topline and bottom-line growth, continuing the momentum of the previous quarters. The growth reflects the positive response of consumers, patients and health care professionals (HCPs) to our science-backed superior healthcare products and innovations amid growing consumer focus on preventive health. It also demonstrates the impact of our strong retail execution, new consumer communication and HCP awareness initiatives and strengthened go-to-market and supply chain capabilities.

We are delivering balanced growth and value creation for all our stakeholders, driven by our strategy that is centred on a focused portfolio of quality, trusted and highly recommended brands where performance drives brand choice, superiority (across product, package, brand communication, retail execution and value), constructive disruption, productivity, and an agile accountable organization.”

Result PDF

Pharmaceuticals company Procter & Gamble Health announced Q1FY27 results

Financial Highlights:

  • Revenue from Operations: The company reported revenue from operations of Rs 36,371 lakh in Q1FY27, representing a growth of 7.37% compared to Rs 33,874 lakh in Q1FY26. On a sequential basis, revenue decreased by 1.82% from Rs 37,045 lakh in Q4FY26.
  • Total Income: Total income for Q1FY27 stood at Rs 36,759 lakh, an increase of 7.24% over Rs 34,277 lakh in Q1FY26. Compared to Q4FY26, total income saw a marginal decline of 1.83% from Rs 37,445 lakh.
  • Profit Before Tax (PBT): The company achieved a PBT of Rs 12,912 lakh in Q1FY27, a significant increase of 45.39% from Rs 8,881 lakh in Q1FY26. Sequentially, PBT declined by 3.07% from Rs 13,321 lakh in Q4FY26. The Q1FY27 PBT includes an exceptional gain of Rs 3,180 lakh.
  • Net Profit for the Period: Net profit stood at Rs 9,615 lakh in Q1FY27, registering a growth of 45.29% compared to Rs 6,618 lakh in Q1FY26. On a QoQ basis, net profit grew by 1.64% from Rs 9,460 lakh in Q4FY26.
  • Total Comprehensive Income: The total comprehensive income for Q1FY27 was Rs 9,646 lakh, up by 47.20% from Rs 6,553 lakh in Q1FY26 and up 5.23% from Rs 9,167 lakh in Q4FY26.
  • Earnings Per Share (EPS): Basic and diluted EPS (after exceptional items) for Q1FY27 was Rs 57.92, compared to Rs 39.87 in Q1FY26 and Rs 56.99 in Q4FY26.

Business Highlights

  • Segment Performance: The company operates in a single primary reportable segment, namely "Pharmaceuticals," as identified under Ind AS 108.
  • Exceptional Item: During Q1FY27, the company sold its office premises property in Worli for a total consideration of Rs 3,334 lakh. With the carrying amount of the property at Rs 154 lakh, the transaction resulted in an exceptional gain of Rs 3,180 lakh.
  • Audit Opinion: The statutory auditors, M/s Haribhakti & Co. LLP, have issued a Limited Review Report with an unmodified conclusion on the financial results for the quarter ended June 30, 2026.

Milind Thatte, Managing Director, P&G Health India, said, “We are happy to start the Financial Year 2026-2027 on a strong note, carrying forward the growth momentum of the previous fiscal. We delivered a strong quarter with sustained top-line and bottom-line growth. This growth is enabled by the consumer response to our science-backed superior innovations, new consumer communication initiatives and strengthened go-to-market and supply chain capabilities.

We are delivering balanced growth and value creation for all our stakeholders, driven by our strategy that is centred on a focused portfolio of quality, trusted and highly recommended brands where performance drives brand choice; superiority (across product, package, brand communication, retail execution and value), constructive disruption, productivity, and an agile accountable organization.”

Result PDF

Pharmaceuticals company Procter & Gamble Health announced Q3FY26 results

Financial Highlights:

  • The company’s Revenue from Operations for Q3FY26 stood at Rs 37,045 lakh, representing a marginal decrease of 0.91% on a QoQ basis compared to Rs 37,386 lakh in Q2FY26, and an increase of 19.12% on a YoY basis compared to Rs 31,099 lakh in Q3FY25.
  • Total Income for the quarter ended March 31, 2026, was Rs 37,445 lakh, showing a decrease of 1.00% QoQ from Rs 37,822 lakh and an increase of 19.21% YoY from Rs 31,410 lakh.
  • Profit Before Tax (PBT) for Q3FY26 was Rs 13,321 lakh, reflecting a growth of 22.41% QoQ from Rs 10,882 lakh and a significant growth of 69.63% YoY from Rs 7,853 lakh.
  • Net Profit for the quarter reached Rs 9,460 lakh, an increase of 21.92% compared to Rs 7,759 lakh in the preceding quarter and a growth of 54.63% compared to Rs 6,118 lakh in the corresponding quarter of the previous year.
  • Earnings per equity share (EPS) for Q3FY26 was Rs 56.99 (not annualised), compared to Rs 46.74 in Q2FY26 and Rs 36.86 in Q3FY25.

Business Highlights:

  • Segment Performance: The company has identified Pharmaceuticals as its single primary reportable segment in accordance with Ind AS 108.
  • Dividend Recommendation: The Board of Directors has recommended a final dividend of Rs 45 per equity share (nominal value of Rs 10 each) for the financial year ended March 31, 2026. This is subject to the approval of shareholders at the ensuing 59th Annual General Meeting.
  • Operational Structure: The company does not have any subsidiary, associate, or joint venture as of March 31, 2026.
  • Labour Codes Update: The company evaluated the impact of the new Labour Codes (2020) and assessed that any incremental impact is not material, as the current salary structure is in line with the requirements.

Milind Thatte, Managing Director, Procter & Gamble Health, said: “We delivered a strong year with consistent top-line and bottom-line growth. We continued to invest across the value chain to address the evolving needs of our consumers and healthcare professionals. These include superior innovations that are backed by science to help our consumers live healthier and more vibrant lives, and consumer communication initiatives, as well as strengthened go-to-market and supply chain capabilities.

We are delivering sustainable, balanced growth and value creation for all our stakeholders, driven by our strategy that is centred on a focused portfolio of quality, trusted and highly recommended brands where performance drives brand choice; superiority (across product, package, brand communication, retail execution and value), constructive disruption, productivity, and an agile accountable organization.”

Note: The company's financial year-end is in June month.

Result PDF

Pharmaceuticals company Procter & Gamble Health announced Q3FY26 results

  • Revenue: Rs 37,386 lakh against Rs 30,977 lakh during Q3FY25, change 21%.
  • PBT: Rs 10,882 lakh against Rs 12,169 lakh during Q3FY25, change -11%.
  • PAT: Rs 7,759 lakh against Rs 9,090 lakh during Q3FY25, change -15%.
  • EPS: Rs 46.74 for Q3FY26.

Milind Thatte, Managing Director, P&G Health, said: “We delivered a strong top-line growth in the quarter, continuing the momentum from the first half of the financial year. This comes behind our strategic efforts across the value chain, including new innovations like Livogen Iron Gummies and Neurobion Nerve Pain Relief Cream, and strengthening of supply chain capabilities. We remain committed towards addressing the evolving needs of our consumers, customers and healthcare professionals, via superior brand building, go to market initiatives, and innovations backed by science to help our consumers live healthier and more vibrant lives.

We are delivering sustainable, balanced growth and value creation for all our stakeholders, driven by our strategy that is centred on a focused portfolio of quality, trusted, and highly recommended brands where performance drives brand choice; superiority (across product, package, brand communication, retail execution and value), constructive disruption and an agile accountable organization.”

The Company has declared an interim dividend of Rs 160 per equity share (including one-time special dividend of Rs 50 per share) for the FY26.

Result PDF

Pharmaceuticals company Procter & Gamble Health announced Q1FY26 results

  • Company delivered a strong performance with sales of Rs 333 crore, up 20% versus a year ago.
  • Profit After Tax (PAT) stood at Rs 66 crore, versus Rs 17 crore a year ago.

Milind Thatte, Managing Director, P&G Health India, said: "We are pleased with the continued momentum and strong start to the FY26. These results are a reflection of our commitment towards addressing the evolving needs of our consumers and healthcare professionals, via superior brand building and go to market initiatives while improving supply chain capabilities.

“Our strategy, centered on a focused portfolio of quality, trusted, and highly recommended brands where performance drives brand choice; superiority (across product, package, brand communication, retail execution and value), constructive disruption and an agile accountable organization, is delivering balanced and sustainable growth results. We continue to drive engagement for our consumers and healthcare professionals alike, through innovation backed by science and meaningful interventions to make life a little better every day”.

Result PDF

Pharmaceuticals company Procter & Gamble Health announced Q3FY25 results

Q3FY25 Financial Highlights:

  • The third quarter reported sales of Rs 304 crore, up 23% versus the comparable period previous year
  • PAT of Rs 61 crore, up 31% versus comparable period a year ago, owing to superior brand building activities and supported by strengthened supply chain and go-to-market capabilities.
  • The Board of Directors has recommended a final dividend of Rs 45 per Equity Share, for the Financial Year ending March 31, 2025

Commenting on the results, Milind Thatte, Managing Director, P&G Health India, said, “This was a period of purposeful transformation and acceleration. We invested in initiatives to address the changing needs of our consumers and healthcare professionals, while strengthening our go-to-market and supply chain capabilities. Our strategy - centered on a focused product portfolio, superiority, productivity, constructive disruption, and an agile and accountable organization structure, helped us build a strong foundation for long-term growth. This integrated strategy continues to guide our efforts to generate sustainable, balanced top- and bottom-line growth, along with value creation for our consumers, customers, and shareholders alike”

Result PDF

Pharmaceuticals company Procter & Gamble Health announced Q2FY25 results

  • The Company reported sales of Rs 304 crore, flat versus a year ago.
  • The Profit After Tax (PAT) for the quarter was Rs 91 crore, up 26% versus a year ago.
  • Profit After Tax (PAT) was up 13% versus a year ago.
  • The Board has declared an interim dividend of Rs 80 per equity share for the FY25. The record date for the dividend will be February 21, 2025.

Milind Thatte, Managing Director, P&G Health India, said: “This quarter was a period of strategic reinforcement as we took proactive steps to strengthen our supply network. We remain committed to our integrated growth strategy of a focused product portfolio, superiority, productivity, constructive disruption, and an agile and accountable organization structure. We are confident that this strategy will enable us to meet the evolving needs of our consumers and healthcare professionals alike.”

Result PDF

Pharmaceuticals company Procter & Gamble Health announced Q1FY25 results

  • Reported sales of Rs 310 crore, change 3% compared to Q1FY24.
  • Profit After Tax (PAT) of Rs 82 crore, change 26% compared to Q1FY24.
  • Operational PAT is up by 8% compared to Q1FY24.

Milind Thatte, Managing Director, P&G Health India, said: “Our firstquarter results represent a sequential improvement. Our strategy, centered on a focused portfolio of quality, trusted, and highly recommended brands where performance drives brand choice; superiority (across product, package, brand communication, retail execution, and value), constructive disruption and an agile accountable organization”.

“We are dedicated to enhancing consumer awareness programs and strengthening our relationships with our customers and stakeholdeRs We continue to invest in initiatives that address the evolving needs of both consumers and healthcare professionals, along with strengthening our go-to-market model. We have also strengthened our reach, distribution, and retail execution, positioning us for long-term competitiveness”.

Result PDF

Pharmaceuticals company Procter & Gamble Health announced Q3FY24 results:

Financial Highlights:

  • Procter & Gamble Health Limited reported a decrease in sales and profit after tax for the Q3FY24. The total sales for the quarter were Rs 248 crore compared to Rs 316 crore a year ago, marking a downturn. Correspondingly, the Profit After Tax (PAT) also declined by 21% to Rs 46 crore.
  • For the nine-month period ending March 31, 2024, P&G Health's sales were recorded at Rs 852 crore, which exhibited a slight reduction from the previous year's sales of Rs 913 crore.
  • The PAT for the nine-month period stood at 184 crore, experiencing a decrease from the Rs 200 crore reported in the prior year.

Milind Thatte, Managing Director, P&G Health India, said, “The Company’s continued efforts to strengthen our reach and distribution with a transformed go-to-market model reflected in a one-time impact on the quarter’s sales owing to the transition and optimization of trade management and inventory. However, we have seen sales recover in the months of March and April.

We continue to drive operational efficiency and explore innovative solutions to accelerate category growth and demand for our portfolio of trusted, quality healthcare brands. The quarter also witnessed prescription growth and share gain for our doctor detailed products indicating a robust demand, and increased efforts to improve awareness of our self-select products.

We remain confident in our integrated growth strategy of a focused product portfolio where performance drives brand choice, superiority, productivity, constructive disruption, and an agile and accountable organization structure to help drive growth and value creation,”he added.

Result PDF

Pharmaceuticals company Procter & Gamble Health announced Q2FY24 results:

  • In a challenging operating environment, the company reported sales of Rs 304 crore, at par vs a year ago.
  • The Profit After Tax (PAT) for the quarter was Rs 72 crore, down 6% vs year ago, owing to one-time items in the quarter.
  • Excluding this one-time impact, Profit After Tax (PAT) was up by 2% vs a year ago.

Milind Thatte, Managing Director, P&G Health India, said, “This has been a challenging quarter for the Company on account of an overall slowdown in the Vitamins, Minerals and Supplements category coupled with a delayed seasonal onset. The team continued to stay resilient. With improved productivity, efficiency and continued strategic investments, we have been able to deliver a modest topline and bottom-line.

We remain committed to our integrated growth strategy of a focused product portfolio, superiority, productivity, constructive disruption, and an agile and accountable organization structure. We are confident that this strategy combined with our operational agility will help us navigate the mid-term and deliver balanced growth.”

 

Result PDF

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Get it on google Play Store Download on the App Store
market app